Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation-Reference-Cited by-同舟云学术

Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation

Published:2020-01-06 Issue:2 Volume:130 Page:733-747
ISSN:0021-9738
Container-title:Journal of Clinical Investigation
language:en
Short-container-title:

Author:

Prockop Susan,Doubrovina Ekaterina,Suser Stephanie,Heller Glenn,Barker Juliet^ORCID,Dahi Parastoo,Perales Miguel A.,Papadopoulos Esperanza,Sauter Craig,Castro-Malaspina Hugo,Boulad Farid,Curran Kevin J.^ORCID,Giralt Sergio,Gyurkocza Boglarka,Hsu Katharine C.,Jakubowski Ann,Hanash Alan M.,Kernan Nancy A.^ORCID,Kobos Rachel,Koehne Guenther,Landau Heather^ORCID,Ponce Doris^ORCID,Spitzer Barbara,Young James W.,Behr Gerald^ORCID,Dunphy Mark,Haque Sofia,Teruya-Feldstein Julie,Arcila Maria,Moung Christine,Hsu Susan,Hasan Aisha,O’Reilly Richard J.

Publisher

American Society for Clinical Investigation

Subject

General Medicine

Link

https://www.jci.org/articles/view/121127/files/pdf

Reference55 articles.

1. Post-transplant lymphoproliferative disorders;Singavi;Cancer Treat Res,2015

2. High incidence of post transplant lymphoproliferative disorder after antithymocyte globulin-based conditioning and ineffective prediction by day 28 EBV-specific T lymphocyte counts

3. Epstein-Barr virus-related post-transplant lymphoproliferative disorder in solid organ transplant recipients;San-Juan;Clin Microbiol Infect,2014

4. Molecular pathogenesis of B-cell posttransplant lymphoproliferative disorder: what do we know so far?;Morscio;Clin Dev Immunol,2013

5. Post-transplant lymphoproliferative disorders: From epidemiology to pathogenesis-driven treatment

Cited by 148 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Silencing of PD-1 combined with EBV-specific killer T cells for the treatment of EBV-associated B lymphoma;Translational Oncology;2024-02

2. Virus-specific T-cells from third party or transplant donors for treatment of EBV lymphoproliferative diseases arising post hematopoietic cell or solid organ transplantation;Frontiers in Immunology;2024-01-11

3. On behalf of the SFGM‐TC: Real‐life use of third‐party virus‐specific T‐cell transfer in immunocompromised transplanted patients;HemaSphere;2024-01

4. Tabelecleucel for allogeneic haematopoietic stem-cell or solid organ transplant recipients with Epstein–Barr virus-positive post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy (ALLELE): a phase 3, multicentre, open-label trial;The Lancet Oncology;2024-01

5. Miscellaneous Complications of Hematopoietic Cellular Transplantation;Manual of Hematopoietic Cell Transplantation and Cellular Therapies;2024